SI-BONE Inc(SIBN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.33 | Insider Own | 4.9% | Shs Outstand | 44.7M | Perf Week | -1.16% |
| Market Cap | 0.95B | Forward P/E | - | EPS next Y | 17.43% | Insider Trans | -11.34% | Shs Float | 42.6M | Perf Month | 15.32% |
| Enterprise Value | 0.85B | PEG | - | EPS next Q | -0.13 | Inst Own | 106.95% | Short Float | 11.04% | Perf Quarter | 15.07% |
| Income | -0.01B | P/S | 4.45 | EPS this Y | 9.86% | Inst Trans | 6.98% | Short Ratio | 8.34 | Perf Half Y | 60.71% |
| Sales | 0.21B | P/B | 5.2 | EPS next 5Y | 26.24% | ROA | -6.1% | Short Interest | 4.70M | Perf YTD | 7.66% |
| Book/sh | 4.08 | P/C | 6.52 | EPS past 3/5Y | 37.37% 21.79% | ROE | -8.3% | 52W High | -7.49% ($22.95) | Perf Year | 40.13% |
| Cash/sh | 3.26 | P/FCF | - | Sales past 3/5Y | 23.6% 22.32% | ROIC | -6.51% | 52W Low | 84.93% ($11.48) | Perf 3Y | 28.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 40.66% | Gross Margin | 79.53% | Volatility(W/M) | 4.19% 4.04% | Perf 5Y | -5.85% |
| Dividend TTM | - | EV/Sales | 3.97 | Sales Y/Y TTM | 15.3% | Oper. Margin | -8.31% | ATR (14) | 0.81 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.55 | EPS Q/Q | 36.09% | Profit Margin | -6.85% | RSI (14) | 58.65 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.15 | Sales Q/Q | 15.18% | SMA20 | 4.12% ($20.39) | Beta | 0.66 | Target Price | $25.44 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/11/2 | SMA50 | 9.36% ($19.41) | Rel Volume | 2.21 | Prev Close | $22.41 |
| Employees | 376 | LT Debt/Eq | 0.23 | EPS/Sales Surpr. | 39.8% 1.21% | SMA200 | 29.47% ($16.4) | Avg Volume(3M) | 0.56M | Price | $21.23 |
| IPO | 2018/10/17 | Option/Short | Yes/Yes | Trades | 10104 | Volume | 1,249,200 | Change | -5.27% |
SI-Bone (ticker: SIBN) is a US medical device company that develops implants and surgical techniques for treating sacropelvic disorders, including sacroiliac joint dysfunction, using a minimally invasive approach. Since its founding in 2008, the company has pioneered minimally invasive sacroiliac joint surgery, establishing a unique position in the orthopedic and spinal medical device market.
Over the past 1 year, on the higher side
7% below its 1-year high.
Traded more than usual. That is 221% of its average volume.
Next earnings report: November 2
That is today.
SIBN has a sound balance sheet but weak earning power
Of every $100 in sales, $8.31 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +9.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $445. Peers typically go for $326.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -5.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 107.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #44 of 142 in the industry
Based on market cap of $951M.
FAQ
What kind of company is SIBN?
SIBN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of SIBN?
The market cap of SIBN is approximately $951M, ranking 2,607 within its sector.
What is the 52-week high and low for SIBN?
SIBN has recorded a 52-week high of $22.95 and a low of $11.48.
